AR-NcoR Interaction as a Therapeutic Target for Prostate Cancer Prevention and Treatment
Abstract
Aim I is to determine the precise molecular basis for NCoR binding to the RU486 liganded AR. We have now published our data showing the AR N-terminus makes a critical contribution to NCoR binding (Hodgson, et al. 2005). Our recent not yet published results show that the NI CoRNR box of NCoR mediates the interaction between NCoR and the AR ligand binding domain. Aim 2 is to determine whether NCoR recruitment can suppress androgen independent expression of AR regulated genes and prostate cancer growth, and identify molecular markers that predict whether RU486 (or related drugs) will be effective in particular prostate cancers in vivo. Our recent data have shown that RU486 can markedly repress the growth of androgen independent 04-2 prostate cancer cells, and that this correlates with down regulation of AR regulated genes. Taken together, these results reflect substantial progress towards determining the structural basis for AR-NCoR interaction (Aim I) and determining whether this interaction can be exploited to treat prostate cancer (Aim 2).
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2005
- Accession Number
- ADA444796
Entities
People
- Steven P Balk
Organizations
- Beth Israel Deaconess Medical Center